Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3403-3409

  Sugimoto, Koji ^a   Shimada, Mitsuo ^a   Utsunomiya, Toru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Iwahashi, Shuichi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Histone deacetylase inhibitor; Pancreatic cancer; Pegylated interferon ; Valproic acid

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE INHIBITOR; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; PEGINTERFERON ALPHA; VALPROIC ACID; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CASPASE; HISTONE DEACETYLASE INHIBITOR; IFNAR1 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR; MACROGOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; BIOSYNTHESIS; DRUG POTENTIATION; METABOLISM; PANCREAS TUMOR; PEGYLATED INTERFERON-Α; TUMOR CELL LINE;

HISTONE DEACETYLASE INHIBITOR; PANCREATIC CANCER; PEGYLATED INTERFERON-Α; VALPROIC ACID;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTOR, INTERFERON ALPHA-BETA; VALPROIC ACID;

EID: 84906317361     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jiang H, Du C, Cai M, He H, Chen C, Qiu J and Wu H: An evaluation of neoadjuvant chemoradiotherapy for patients with resectable pancreatic ductal carcinoma. HPB Surg Epub 2013 Jun 20
2. Gillen S, Schuster T, Meyer Z B C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: a systemic review and meta-analysis of response and resection percentages. PLos Med 20;7(4): e1000267, 2010.
3. Goldstein D, Caroll S, Apte M and Keogh G: Modern management of pancreatic cancer. Intern Med J 34(8): 475-478, 2004.
4. Picozzi VJ, Kozarek RA and Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185(5): 476-480, 2003.
5. Neoptolemos J, Stocken D and Friess H: The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
6. Feng W, Zhang B, Cai D and Zou X: Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett. 1;347(2): 183-190, 2014.
7. Konstantinopoulos PA, Karamouzis MV and Papavassiliou AG: Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin Investig Drugs 16(5): 569-571, 2007.
8. Koutsounas I, Giaginis C and Theocharis S: Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 28;19(8): 1173-1181, 2013.
9. Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1): 19-25, 2007.
10. Stypula-Cyrus Y, Damania D, Kunte DP, Cruz MD, Subramanian H, Roy HK and Backman V: HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 28;8(5): e64600, 2013.
11. Dickinson M, Johnstone RW and Prince HM: Histone deacetylase inhibitors: potential targets responsible for their anticancer effect. Invest New Drugs. Suppl 1: S3-20, 2010.
12. Kelly WK and Marks PA: Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2(3): 150157.
13. Marson CM: Histone deacetylase inhibitors: design, structu-reactivity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 9(6): 661-692, 2009.
14. Buggy J J, Cao Z A, Bass K E, Verner E, Balasubramanian S, Lui L, Schultz BE, Young PR and Dairympie SA: CRA-024781, a novel synthetic inhibitor of histone deacetylase enzymes with anti-tumor activity in vitro and in vivo. Mol Cancer Ther 5(5): 1309-1317, 2006.
15. Zhou Y, Xu Y, Wang H, Niu J, Hou H and Jiang Y: Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett 7(1): 203-208, 2014.
16. Li J. Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, Schnolzer M, Mougin C, Aprahamian M, Grekova SP, Raykov Z, Rommelaere J and Marchini A: Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med 5(10): 1537-1555, 2013.
17. Miyake K, Shimada M, Nishioka M, Sugimoto K, Batmunkh E, Uto Y, Nagasawa H and Hori H: The novel hypoxic cell radio-sensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer. Cancer Lett 272(2): 325-335, 2008
18. PfaZ MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
19. Gonzalez AD, Candelaria M, Plascencia CP, Cardenas EP, de la Cruz-Hernandez E and Herrera LA: Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34(3): 206-222, 2008.
20. Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K and Shimada H: A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol 2011: 479013, 2011.
21. Caraglia M, Dicitore A, Marra M, Castiglioni S, Persani L, Sperlongano P, Tagliaferri P, Abbruzzese A and Vitale G: Type I interferons: ancient peptides with still under-discovered anticancer properties. Protein Pept Lett 20(4): 412-423, 2013.
22. Kotredes KP and Gamero AM: Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res 33(4): 162-170, 2013.
23. Bales SR and Chopra IJ: Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res 2011: 102636, 2011.
24. Karakhanova S, Mosi B, Harig S, von Ahn K, Fritz J, Schmidt J, Jager D, Wemer J and Bazhin AV: Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Int J Mol Sci 15(3): 4104-4125, 2014.
25. Papageorgiou A, Kamat A, Benedict WF, Dinney C and McConkey DJ: Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12): 3032-3041, 2006.
26. Steiner T H, Junker U, Henzgen B, Nuske K, Durum SK and Schubert J: Interferon- Alpha Suppresses the Antiapoptotic Effect of NF-kB and Sensitizes Renal Cell Carcinoma Cells in vitro to Chemotherapeutic Drugs. Eur Urol 39(4): 478-483, 2001.
27. Miyake K, Tsuchida K, Sugino H, Imura S, Morine Y, Fujii M and Shimada M: Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother Pharmacol 59(1): 113-26, 2007.
28. Rao-Bindal K, Koshkina NV, Stewart J and Kleinerman ES: The histone deacetylase inhibitor, MS-275(entinostat), downregulates c-FLIP, sensitized osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 13(4): 411-422, 2013.
29. Jazirehi AR and Arle D: Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol 2(1): 55-74, 2013.
30. Papageorgiou A, Dinney CP and McConkey DJ: Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6(6): 872-879, 2007.
31. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr: Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol. 25(6): 1795-1799, 2004.
32. Juengel E, Bhasin M, Libermann T, Barth S, Michaelis M, Cinatl J Jr., Jones J, Hudak L, Jonas D and Blaheta RA: Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase inhibitor valproic acid and interferon-alpha. World J Urol 29(6): 779-786, 2011.
33. Vitale G, van Eijck CH, van Koetsveld ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SW and Hofland LJ: Type I Interferons in the Treatment of Pancreatic Cancer: Mechanisms of Action and Role of Related Receptors. Ann Surg 246(2): 259-268, 2007.
34. Ota H, Nagano H, Doki Y, Sekimoto M, Kondo M, Wada H, Nakamura M, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M and Monden M: Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers. Oncol Rep 16(2): 249-255, 2006.
35. Saidi RF, Williams F, Silberberg B Mittal VK, ReMine SG and Jacobs MJ: Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor. Surgery 139(6): 743-748, 2006.
36. Hoffmann K, Mehrle S, Schmidt J, Buchler MW and Marten A: Interferon-alpha Restitutes the Chemosensitivity in Pancreatic Cancer. Anticancer Research 28(3A): 1499-1508, 2008.
37. Farmer JR, Altschaefl KM, O'Shea KS and Miller DJ: Activation of type I interferon pathway is enhanced in response to human neuronal differentiation. PLoS One 8(3): e58813, 2013.
38. McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R and Tepper MA. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res 24(2): 119-129, 2004.
39. Yanai H, Negishi H and Taniguchi T: The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 1(8): 1376-1386, 2012.
40. Yang D, Thangaraju M, Browning DD, Dong Z, Korchin B, Lev DC, Ganapathy V and Liu K: IFN Regulatory Factor 8 Mediates Apoptosis in Nonhemopoietic Tumor Cells via Regulation of Fas Expression. J Immunol 179(7): 4775-4782, 2007.
41. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T and Matikainen S: IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 24(3): 81-90, 2003.
42. Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K and Abrams SI: Interferon regulatory factor-8 modulates the development of tumor-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med 13(9B): 3939-3950, 2009.
43. Egwuagu C E, Li W, Yu C R, Che Mei Lin M, Chan CC, Nakamura T and Chepelinsky AB: Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25(26): 3670-3679, 2006
44. Tshuikina M, Wiklund H J, Nilsson K and Öberg F: Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma, Exp Hematol 36(12): 1673-1681, 2008
45. Lee K Y, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, Zeng YX, Wong AH, Wang X, Ying J, Srivastava G, Lung ML, Wang LD, Kwok TT, Levi BZ, Chan AT, Sung JJ and Tao Q: Epigenetic disruption of interferon-γ response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas: Methylation of IRF8 in multiple carcinomas. Oncogene 27(39) : 5267-5276, 2008.